Bookbuilding IPO | ₹[.] Cr | Listing at NSE SME |
Bio Medica Laboratories Ltd. has filed a Draft Red Herring Prospectus (DRHP) with the exchange on to raise funds through Initial Public Offer (IPO).
Bio Medica Laboratories Ltd. IPO is a Book Build Issue of 0.38 crore equity shares consisting of a fresh issue of upto 0.34 crore equity shares and an offer for sale (OFS) of upto 0.04 crore equity shares.
The equity shares are proposed to be listed on the NSE SME. Narnolia Financial Services Ltd. is the book running lead manager and Skyline Financial Services Pvt.Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Bio Medica Laboratories IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 37,71,600 shares (agg. up to ₹[.] Cr) |
| Reserved for Market Maker | 1,89,600 shares (agg. up to ₹[.] Cr) |
| Fresh Issue (Ex Market Maker) | 32,05,200 shares (agg. up to ₹[.] Cr) |
| Offer for Sale | 3,76,800 shares of ₹10 (agg. up to ₹[.] Cr) |
| Net Offered to Public | 35,82,000 shares (agg. up to ₹[.] Cr) |
| Share Holding Pre Issue | 91,80,001 shares |
| Share Holding Post Issue | 1,25,74,801 shares |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Fri, Aug 8, 2025 |
| SEBI/Exchange approval received |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50.00% of the Net offer |
| Retail Shares Offered | Not less than 35.00% of the Net offer |
| NII Shares Offered | Not less than 15% of the Net offer |
Bio Medica Laboratories specializes in the manufacturing of pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the-counter (OTC) medications in the form of liquid iand dry powder injectables. These injectables are available in both single-dose and multi-dose formats, serving the needs of both human and veterinary healthcare.
Product portfolio:
It offers comprehensive range of products, including generic drugs, branded pharmaceuticals, over the counter (OTC) products, and other medications.
The company operates on a B2B model, focusing exclusively on contract manufacturing. It develop formulations for various companies in accordance with their specific requirements and product specifications. It is certified for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificate issued by the Food & Drugs Administration, Madhya Pradesh.
It has two manufacturing facilities in Indore, Madhya Pradesh.
Competitive Strengths
Bio Medica Laboratories Ltd.'s revenue increased by 150% and profit after tax (PAT) rose by 292% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 39.12 | 19.53 | 17.57 |
| Total Income | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 9.79 | 2.50 | 0.33 |
| EBITDA | 15.21 | 5.63 | 1.70 |
| NET Worth | 14.73 | 4.94 | 2.44 |
| Reserves and Surplus | 5.55 | 4.84 | 2.34 |
| Total Borrowing | 15.01 | 10.49 | 9.61 |
| Amount in ₹ Crore | |||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment of Loan | 7.25 |
| 2 | Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises | 24.81 |
| 3 | General Corporate Purposes |
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 99.59% |
| ROCE | 48.20% |
| Debt/Equity | 1.02 |
| RoNW | 99.59% |
| PAT Margin | 25.64% |
| EBITDA Margin | 39.83% |
| Pre IPO | Post IPO | |
|---|---|---|
| Promoter Holding | 99.99% |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Lead manager(s) fees | |
| 2 | Underwriting fees | |
| 3 | Market Making fees | |
| 4 | Brokerage, selling commission and upload fees | |
| 5 | Registrars to the issue | |
| 6 | Legal Advisors | |
| 7 | Printing expenses | |
| 8 | Advertising and marketing expenses | |
| 9 | Regulators including stock exchanges | |
| 10 | Others, if any |
Lead Manager Reports
Bio Medica Laboratories IPO is a SME IPO of 37,71,600 equity shares of the face value of ₹10 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .
The Bio Medica Laboratories IPO open and close dates are not available as of now.
Skyline Financial Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Bio Medica Laboratories IPO using UPI as a payment gateway. Zerodha customers can apply in Bio Medica Laboratories IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Bio Medica Laboratories IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Bio Medica Laboratories IPO dates are not announced. Please check back again after some time.
Bio Medica Laboratories IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Bio Medica Laboratories IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Bio Medica Laboratories IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Bio Medica Laboratories IPO allotment status.
The Bio Medica Laboratories IPO listing date is not yet announced. The tentative date of listing is .
